We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ERS Genomics Licenses Genome-Editing Patents to Regeneron Pharmaceuticals
News

ERS Genomics Licenses Genome-Editing Patents to Regeneron Pharmaceuticals

ERS Genomics Licenses Genome-Editing Patents to Regeneron Pharmaceuticals
News

ERS Genomics Licenses Genome-Editing Patents to Regeneron Pharmaceuticals

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ERS Genomics Licenses Genome-Editing Patents to Regeneron Pharmaceuticals"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ERS Genomics holds rights to foundational CRISPR-Cas9 patent portfolio from Dr. Emmanuelle Charpentier, an inventor of the breakthrough gene-editing technology.

"We are pleased to include Regeneron, a leading biopharmaceutical company, into our portfolio of licensees,” said Shaun Foy, CEO and Founder of ERS Genomics. “Genome editing has many applications in drug discovery and development and making the CRISPR-Cas9 patents widely available to biotechnology and pharmaceutical companies is an important part of ERS Genomics’ strategy."

Dr. Emmanuelle Charpentier’s research unveiled the key components and mechanisms of the CRISPR-Cas9 system, leading to the landmark publication with Jennifer Doudna, (Jinek et al., 2012), which laid the foundation for the use of CRISPR-Cas9 as a highly versatile and precise genome-editing tool.

Financial details of the agreement were not disclosed.

Advertisement